Search our website

Press Releases

VBI Vaccines Announces Poster Presentation at EASL 2023
June 7th, 2023
VBI Vaccines Reports First Quarter 2023 Financial Results
May 15th, 2023
VBI Vaccines Appoints Vaughn Himes to Board of Directors
April 25th, 2023
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
April 4th, 2023
VBI Vaccines Reports Full Year 2022 Financial Results
March 13th, 2023
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
February 23rd, 2023
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
February 15th, 2023
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
December 8th, 2022
CEPI Boosts ‘Coronavirus X’ Vaccine Search with Expanded VBI Vaccines Deal
December 6th, 2022
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
November 22nd, 2022
VBI Vaccines to Participate in Upcoming Investor Conferences
November 14th, 2022
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
November 11th, 2022
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10th, 2022
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 17th, 2022
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
October 12th, 2022
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
September 29th, 2022
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
September 21st, 2022
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
September 15th, 2022
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
September 8th, 2022
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8th, 2022

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top